Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309183903> ?p ?o ?g. }
- W4309183903 abstract "Background The diagnostic challenges associated with the COVID‐19 pandemic resulted in rapid development of diagnostic test methods for detecting SARS‐CoV‐2 infection. Serology tests to detect the presence of antibodies to SARS‐CoV‐2 enable detection of past infection and may detect cases of SARS‐CoV‐2 infection that were missed by earlier diagnostic tests. Understanding the diagnostic accuracy of serology tests for SARS‐CoV‐2 infection may enable development of effective diagnostic and management pathways, inform public health management decisions and understanding of SARS‐CoV‐2 epidemiology. Objectives To assess the accuracy of antibody tests, firstly, to determine if a person presenting in the community, or in primary or secondary care has current SARS‐CoV‐2 infection according to time after onset of infection and, secondly, to determine if a person has previously been infected with SARS‐CoV‐2. Sources of heterogeneity investigated included: timing of test, test method, SARS‐CoV‐2 antigen used, test brand, and reference standard for non‐SARS‐CoV‐2 cases. Search methods The COVID‐19 Open Access Project living evidence database from the University of Bern (which includes daily updates from PubMed and Embase and preprints from medRxiv and bioRxiv) was searched on 30 September 2020. We included additional publications from the Evidence for Policy and Practice Information and Co‐ordinating Centre (EPPI‐Centre) ‘COVID‐19: Living map of the evidence’ and the Norwegian Institute of Public Health ’NIPH systematic and living map on COVID‐19 evidence’. We did not apply language restrictions. Selection criteria We included test accuracy studies of any design that evaluated commercially produced serology tests, targeting IgG, IgM, IgA alone, or in combination. Studies must have provided data for sensitivity, that could be allocated to a predefined time period after onset of symptoms, or after a positive RT‐PCR test. Small studies with fewer than 25 SARS‐CoV‐2 infection cases were excluded. We included any reference standard to define the presence or absence of SARS‐CoV‐2 (including reverse transcription polymerase chain reaction tests (RT‐PCR), clinical diagnostic criteria, and pre‐pandemic samples). Data collection and analysis We use standard screening procedures with three reviewers. Quality assessment (using the QUADAS‐2 tool) and numeric study results were extracted independently by two people. Other study characteristics were extracted by one reviewer and checked by a second. We present sensitivity and specificity with 95% confidence intervals (CIs) for each test and, for meta‐analysis, we fitted univariate random‐effects logistic regression models for sensitivity by eligible time period and for specificity by reference standard group. Heterogeneity was investigated by including indicator variables in the random‐effects logistic regression models. We tabulated results by test manufacturer and summarised results for tests that were evaluated in 200 or more samples and that met a modification of UK Medicines and Healthcare products Regulatory Agency (MHRA) target performance criteria. Main results We included 178 separate studies (described in 177 study reports, with 45 as pre‐prints) providing 527 test evaluations. The studies included 64,688 samples including 25,724 from people with confirmed SARS‐CoV‐2; most compared the accuracy of two or more assays (102/178, 57%). Participants with confirmed SARS‐CoV‐2 infection were most commonly hospital inpatients (78/178, 44%), and pre‐pandemic samples were used by 45% (81/178) to estimate specificity. Over two‐thirds of studies recruited participants based on known SARS‐CoV‐2 infection status (123/178, 69%). All studies were conducted prior to the introduction of SARS‐CoV‐2 vaccines and present data for naturally acquired antibody responses. Seventy‐nine percent (141/178) of studies reported sensitivity by week after symptom onset and 66% (117/178) for convalescent phase infection. Studies evaluated enzyme‐linked immunosorbent assays (ELISA) (165/527; 31%), chemiluminescent assays (CLIA) (167/527; 32%) or lateral flow assays (LFA) (188/527; 36%). Risk of bias was high because of participant selection (172, 97%); application and interpretation of the index test (35, 20%); weaknesses in the reference standard (38, 21%); and issues related to participant flow and timing (148, 82%). We judged that there were high concerns about the applicability of the evidence related to participants in 170 (96%) studies, and about the applicability of the reference standard in 162 (91%) studies. Average sensitivities for current SARS‐CoV‐2 infection increased by week after onset for all target antibodies. Average sensitivity for the combination of either IgG or IgM was 41.1% in week one (95% CI 38.1 to 44.2; 103 evaluations; 3881 samples, 1593 cases), 74.9% in week two (95% CI 72.4 to 77.3; 96 evaluations, 3948 samples, 2904 cases) and 88.0% by week three after onset of symptoms (95% CI 86.3 to 89.5; 103 evaluations, 2929 samples, 2571 cases). Average sensitivity during the convalescent phase of infection (up to a maximum of 100 days since onset of symptoms, where reported) was 89.8% for IgG (95% CI 88.5 to 90.9; 253 evaluations, 16,846 samples, 14,183 cases), 92.9% for IgG or IgM combined (95% CI 91.0 to 94.4; 108 evaluations, 3571 samples, 3206 cases) and 94.3% for total antibodies (95% CI 92.8 to 95.5; 58 evaluations, 7063 samples, 6652 cases). Average sensitivities for IgM alone followed a similar pattern but were of a lower test accuracy in every time slot. Average specificities were consistently high and precise, particularly for pre‐pandemic samples which provide the least biased estimates of specificity (ranging from 98.6% for IgM to 99.8% for total antibodies). Subgroup analyses suggested small differences in sensitivity and specificity by test technology however heterogeneity in study results, timing of sample collection, and smaller sample numbers in some groups made comparisons difficult. For IgG, CLIAs were the most sensitive (convalescent‐phase infection) and specific (pre‐pandemic samples) compared to both ELISAs and LFAs (P < 0.001 for differences across test methods). The antigen(s) used (whether from the Spike‐protein or nucleocapsid) appeared to have some effect on average sensitivity in the first weeks after onset but there was no clear evidence of an effect during convalescent‐phase infection. Investigations of test performance by brand showed considerable variation in sensitivity between tests, and in results between studies evaluating the same test. For tests that were evaluated in 200 or more samples, the lower bound of the 95% CI for sensitivity was 90% or more for only a small number of tests (IgG, n = 5; IgG or IgM, n = 1; total antibodies, n = 4). More test brands met the MHRA minimum criteria for specificity of 98% or above (IgG, n = 16; IgG or IgM, n = 5; total antibodies, n = 7). Seven assays met the specified criteria for both sensitivity and specificity. In a low‐prevalence (2%) setting, where antibody testing is used to diagnose COVID‐19 in people with symptoms but who have had a negative PCR test, we would anticipate that 1 (1 to 2) case would be missed and 8 (5 to 15) would be falsely positive in 1000 people undergoing IgG or IgM testing in week three after onset of SARS‐CoV‐2 infection. In a seroprevalence survey, where prevalence of prior infection is 50%, we would anticipate that 51 (46 to 58) cases would be missed and 6 (5 to 7) would be falsely positive in 1000 people having IgG tests during the convalescent phase (21 to 100 days post‐symptom onset or post‐positive PCR) of SARS‐CoV‐2 infection. Authors' conclusions Some antibody tests could be a useful diagnostic tool for those in whom molecular‐ or antigen‐based tests have failed to detect the SARS‐CoV‐2 virus, including in those with ongoing symptoms of acute infection (from week three onwards) or those presenting with post‐acute sequelae of COVID‐19. However, antibody tests have an increasing likelihood of detecting an immune response to infection as time since onset of infection progresses and have demonstrated adequate performance for detection of prior infection for sero‐epidemiological purposes. The applicability of results for detection of vaccination‐induced antibodies is uncertain." @default.
- W4309183903 created "2022-11-24" @default.
- W4309183903 creator A5000280447 @default.
- W4309183903 creator A5000911087 @default.
- W4309183903 creator A5006199321 @default.
- W4309183903 creator A5011978339 @default.
- W4309183903 creator A5012637147 @default.
- W4309183903 creator A5022568658 @default.
- W4309183903 creator A5025393622 @default.
- W4309183903 creator A5025456912 @default.
- W4309183903 creator A5037205074 @default.
- W4309183903 creator A5042080706 @default.
- W4309183903 creator A5046390808 @default.
- W4309183903 creator A5047681399 @default.
- W4309183903 creator A5049079453 @default.
- W4309183903 creator A5050066824 @default.
- W4309183903 creator A5058507347 @default.
- W4309183903 creator A5058597472 @default.
- W4309183903 creator A5063896163 @default.
- W4309183903 creator A5064076333 @default.
- W4309183903 creator A5065037512 @default.
- W4309183903 creator A5066251369 @default.
- W4309183903 creator A5066861352 @default.
- W4309183903 creator A5069468876 @default.
- W4309183903 creator A5070557002 @default.
- W4309183903 creator A5075245317 @default.
- W4309183903 creator A5079154058 @default.
- W4309183903 creator A5081258369 @default.
- W4309183903 creator A5082566367 @default.
- W4309183903 creator A5091649890 @default.
- W4309183903 date "2022-11-17" @default.
- W4309183903 modified "2023-10-17" @default.
- W4309183903 title "Antibody tests for identification of current and past infection with SARS-CoV-2" @default.
- W4309183903 cites W2107638293 @default.
- W4309183903 cites W2123300483 @default.
- W4309183903 cites W2785704959 @default.
- W4309183903 cites W2991792334 @default.
- W4309183903 cites W3001195213 @default.
- W4309183903 cites W3007104924 @default.
- W4309183903 cites W3008884953 @default.
- W4309183903 cites W3008962515 @default.
- W4309183903 cites W3009566214 @default.
- W4309183903 cites W3009823731 @default.
- W4309183903 cites W3009931727 @default.
- W4309183903 cites W3010437616 @default.
- W4309183903 cites W3010577082 @default.
- W4309183903 cites W3011268229 @default.
- W4309183903 cites W3011590696 @default.
- W4309183903 cites W3011734200 @default.
- W4309183903 cites W3011932114 @default.
- W4309183903 cites W3012078461 @default.
- W4309183903 cites W3012562157 @default.
- W4309183903 cites W3012602168 @default.
- W4309183903 cites W3012650581 @default.
- W4309183903 cites W3012756997 @default.
- W4309183903 cites W3012846954 @default.
- W4309183903 cites W3012995139 @default.
- W4309183903 cites W3013178230 @default.
- W4309183903 cites W3013213522 @default.
- W4309183903 cites W3013344703 @default.
- W4309183903 cites W3013498633 @default.
- W4309183903 cites W3013798611 @default.
- W4309183903 cites W3013893137 @default.
- W4309183903 cites W3013896848 @default.
- W4309183903 cites W3013928032 @default.
- W4309183903 cites W3013985547 @default.
- W4309183903 cites W3014260755 @default.
- W4309183903 cites W3014682585 @default.
- W4309183903 cites W3014721277 @default.
- W4309183903 cites W3014853770 @default.
- W4309183903 cites W3015060295 @default.
- W4309183903 cites W3015363367 @default.
- W4309183903 cites W3015406037 @default.
- W4309183903 cites W3015434703 @default.
- W4309183903 cites W3015940872 @default.
- W4309183903 cites W3016000491 @default.
- W4309183903 cites W3016165935 @default.
- W4309183903 cites W3016214835 @default.
- W4309183903 cites W3016275653 @default.
- W4309183903 cites W3016611530 @default.
- W4309183903 cites W3016722972 @default.
- W4309183903 cites W3016822540 @default.
- W4309183903 cites W3016941664 @default.
- W4309183903 cites W3016977245 @default.
- W4309183903 cites W3017074092 @default.
- W4309183903 cites W3017101752 @default.
- W4309183903 cites W3017106545 @default.
- W4309183903 cites W3017186084 @default.
- W4309183903 cites W3017325113 @default.
- W4309183903 cites W3017380558 @default.
- W4309183903 cites W3017773635 @default.
- W4309183903 cites W3017815440 @default.
- W4309183903 cites W3017902602 @default.
- W4309183903 cites W3018013720 @default.
- W4309183903 cites W3018033259 @default.
- W4309183903 cites W3018083407 @default.
- W4309183903 cites W3018166943 @default.
- W4309183903 cites W3018432443 @default.
- W4309183903 cites W3018469982 @default.
- W4309183903 cites W3018638113 @default.